Conference Coverage

The case for being open-minded about medical marijuana


 

REPORTING FROM NPA 2018

Medical indications for cannabis in various states include 53 conditions, he said, such as cancer, glaucoma, AIDS, hepatitis C, amyotrophic lateral sclerosis, Crohn’s disease, Parkinson’s disease, and multiple sclerosis. However, data suggest that most people with medical cannabis cards do not have one of those conditions. More than 50 trials of cannabinoids, including cannabis, have been conducted, “and we definitely need a lot more,” Dr. Hill continued. “About half of the studies show positive effects for chronic pain, neuropathic pain, and spasticity associated with MS.”

Resources Dr. Hill recommended for clinicians include a review that he published in JAMA (2015;313[24]:2474-83), and a review of cannabis and pain that he coauthored that was published in the journal Cannabis and Cannabinoid Research (2017;2[1]:96-104), and a free downloadable publication from he National Academies Press entitled “Health Effects of Cannabis and Cannabinoid Research: The Current State of Evidence and Recommendations for Research.” One passage from that document reads as follows: “Despite the extensive changes in policy at the state level and the rapid rise in the use of cannabis both for medical purposes and for recreational use, conclusive evidence regarding the short- and long-term health effects (harms and benefits) of cannabis use remains elusive. A lack of scientific research has resulted in a lack of information on the health implications of cannabis use, which is a significant public health concern for vulnerable populations such as pregnant women and adolescents. Unlike other substances whose use may confer risk, such as alcohol or tobacco, no accepted standards exist to help guide individuals as they make choices regarding the issues of if, when, where, and how to use cannabis safely and, in regard to therapeutic uses, effectively.”

Dr. Hill disclosed that he has received research grants from National Institute on Drug Abuse, the Brain and Behavior Research Foundation, the American Lung Association, the Greater Boston Council on Alcoholism, and the Peter G. Dodge Foundation. He also receives book royalties from Hazelden Publishing.

dbrunk@frontlinemedcom.com

Pages

Recommended Reading

Use of opioids, SSRIs linked to increased fracture risk in RA
MDedge Psychiatry
CMS to enlist Medicare Part D plans to combat opioid abuse
MDedge Psychiatry
Fremanezumab may reduce chronic migraine frequency
MDedge Psychiatry
New buprenorphine formulation approved for medication-assisted treatment
MDedge Psychiatry
Persistent opioid use a risk after surgery in teens and young adults
MDedge Psychiatry
Serotonin syndrome warnings magnify its rare probability
MDedge Psychiatry
Serotonin syndrome risk with triptans and antidepressants ‘very low’
MDedge Psychiatry
Opioid deaths in the ED increase nationally
MDedge Psychiatry
Nonopioid analgesics have no major disadvantages vs. opioids for chronic pain
MDedge Psychiatry
Opioid prescriptions got shorter in 2017
MDedge Psychiatry

Related Articles